RET and renal cell carcinoma: In the FGF overexpression setting, lenvatinib, an oral inhibitor of FGFR, VEGF 1-3, PDGFR α, RET, and KIT, is able to overcome the FGF resistance mechanism and has demonstrated activity in the first line setting in combination with pembrolizumab and in subsequent treatment lines in combination with everolimus of patients with advanced RCC [139].